Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 11:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,462 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metastatic Nonsmall Cell Lung Cancer Clear all
Active, not recruiting Phase 3 Interventional Results available

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

NCT04656652
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
DS-1062a, Docetaxel
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Chandler, Arizona • Anaheim, California • Glendale, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 10, 2026, 11:05 AM EDT
Terminated Phase 1 Interventional

C-TIL051 in Non-Small Cell Lung Cancer

NCT05676749
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
C-TIL051
Biological
Lead sponsor
AbelZeta Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
New Orleans, Louisiana • Raleigh, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 10, 2026, 11:05 AM EDT
Active, not recruiting Phase 1 Interventional

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

NCT04886804
View directory record Official record
Conditions
Neoplasm Metastasis, Non-Small Cell Lung Cancer
Interventions
zongertinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Beverly Hills, California • Duarte, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 10, 2026, 11:05 AM EDT
Not listed Phase 1 Interventional

AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00324597
View directory record Official record
Conditions
Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
gemcitabine hydrochloride, motesanib diphosphate, pharmacological study
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 10, 2026, 11:05 AM EDT
Active, not recruiting Phase 1 Interventional

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

NCT05650879
View directory record Official record
Conditions
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
Interventions
ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine
Drug
Lead sponsor
Enliven Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Aurora, Colorado • Orlando, Florida • Plantation, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 10, 2026, 11:05 AM EDT
Active, not recruiting Not applicable Interventional

NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer

NCT04986670
View directory record Official record
Conditions
Lung Cancer, Small Cell, Lung Cancer Metastatic, Lung Cancer Recurrent, Treatment Side Effects, Lung Cancer, Non-small Cell, Nutritional Imbalance
Interventions
Nutritional Counseling, Medically Tailored Meals (MTMs), Nutrition Prescription, Nutrition Assessment, Nutrition Toolkit, Monthly Emails
Behavioral · Other
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 100 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 10, 2026, 11:05 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

NCT01860040
View directory record Official record
Conditions
Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer, Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer
Interventions
Cisplatin, Pemetrexed, Gemcitabine
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 10, 2026, 11:05 AM EDT
Completed Phase 1 Interventional

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

NCT02892123
View directory record Official record
Conditions
HER2-expressing Cancers
Interventions
ZW25 (Zanidatamab), Paclitaxel, Capecitabine, Vinorelbine, Tucatinib
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 10, 2026, 11:05 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

NCT04303780
View directory record Official record
Conditions
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Interventions
AMG 510, Docetaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
54
States / cities
Anaheim, California • Duarte, California • Long Beach, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 10, 2026, 11:05 AM EDT
Terminated Phase 1 Interventional Results available

A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC

NCT02346370
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
PEGylated recombinant human hyaluronidase PH20, Docetaxel
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Encinitas, California • Fresno, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 10, 2026, 11:05 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

NCT04424641
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC), Squamous Cell Carcinoma of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Bladder Cancer, Uterine Cancer
Interventions
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 10, 2026, 11:05 AM EDT
Completed No phase listed Observational

Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer

NCT00579683
View directory record Official record
Conditions
Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC)
Interventions
Tumor core biopsy for RNA isolation
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 10, 2026, 11:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

NCT04068896
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
Interventions
NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane, NGM120 100mg with Gemcitabine and Abraxane, NGM120 100mg Q3W, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 10, 2026, 11:05 AM EDT
Completed Phase 2 Interventional Results available

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

NCT03940703
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Tepotinib, Osimertinib
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
49
States / cities
Yuma, Arizona • Fountain Valley, California • Long Beach, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 10, 2026, 11:05 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer

NCT00003072
View directory record Official record
Conditions
Lung Cancer, Neurotoxicity, Ovarian Cancer
Interventions
amifostine trihydrate, carboplatin, paclitaxel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
4
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2012 · Synced Oct 10, 2026, 11:05 AM EDT
Terminated Phase 2 Interventional Results available

Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease

NCT02469701
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer, Metastatic Lung Cancer, NSCLC
Interventions
nivolumab and ablation
Drug
Lead sponsor
howard safran
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 10, 2026, 11:05 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer

NCT00986674
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cixutumumab, carboplatin, paclitaxel, cetuximab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
249
States / cities
Stanford, California • Aurora, Colorado • Boulder, Colorado + 171 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2014 · Synced Oct 10, 2026, 11:05 AM EDT
Withdrawn Phase 1 Interventional

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

NCT05693090
View directory record Official record
Conditions
NSCLC
Interventions
Tipifarnib, Osimertinib
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Santa Rosa, California • Ridgewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 10, 2026, 11:05 AM EDT
Terminated Phase 1 Interventional

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

NCT02313012
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
CC-90003
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Los Angeles, California • New Haven, Connecticut • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 10, 2026, 11:05 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00118131
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, docetaxel
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
13
States / cities
East Brunswick, New Jersey • Edison, New Jersey • Freehold, New Jersey + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 10, 2026, 11:05 AM EDT
Active, not recruiting Phase 2 Interventional

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

NCT05853575
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
Interventions
Adagrasib
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Santa Rosa, California • Kansas City, Missouri • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 10, 2026, 11:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients

NCT01999881
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
exercise intervention, standard follow-up care, quality-of-life assessment, laboratory biomarker analysis
Behavioral · Procedure · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 10, 2026, 11:05 AM EDT
Completed Phase 2 Interventional

Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00100854
View directory record Official record
Conditions
Lung Cancer
Interventions
erlotinib hydrochloride, fulvestrant
Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 10, 2026, 11:05 AM EDT
Completed Phase 2 Interventional Results available

Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00550537
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, gene expression analysis, protein expression analysis, proteomic profiling, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
7
States / cities
Gainesville, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 10, 2026, 11:05 AM EDT